Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial
Background: The effectiveness and safety of herbal medicine Huashibaidu granule (HSBD) in treating mild Coronavirus Disease 2019 (COVID-19) patients infected with SARS-CoV-2 remain to be identified. We aimed to evaluate the effectiveness of HSBD in mild COVID-19 patients. Methods: A prospective, non...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | Integrative Medicine Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221342202300029X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849695133150216192 |
|---|---|
| author | Bowu Chen Yan Xue Hua Jing Xiaodong Wang Peimin Zhu Weiwei Hao Man Li Yueqiu Gao |
| author_facet | Bowu Chen Yan Xue Hua Jing Xiaodong Wang Peimin Zhu Weiwei Hao Man Li Yueqiu Gao |
| author_sort | Bowu Chen |
| collection | DOAJ |
| description | Background: The effectiveness and safety of herbal medicine Huashibaidu granule (HSBD) in treating mild Coronavirus Disease 2019 (COVID-19) patients infected with SARS-CoV-2 remain to be identified. We aimed to evaluate the effectiveness of HSBD in mild COVID-19 patients. Methods: A prospective, non-randomized, controlled study in mild COVID-19 patients was conducted in Shanghai, China, from April 8 to May 6, 2022. Finally, 360 mild COVID-19 patients received HSBD (orally 20 g twice daily for 7 days), and 368 patients received herbal medicine placebo (orally 20 g twice daily for 7 days). The primary endpoints were the negative conversion rate of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the negative conversion time. Secondary endpoints included the hospitalized days and the improvement in the clinical condition. Results: The negative conversion rate of SARS-CoV-2 at 7 days posttreatment in the HSBD group was higher than that in the control group (95.28% vs. 82.61%, P < 0.001). The median negative conversion time in the HSBD group was markedly decreased by 2 days compared with the control group (3 [3–6] vs. 5 [4–7], P < 0.001). In addition, the median hospitalized day was shortened in the HSBD group by 1 day compared with the control group (6 [4–7] vs. 7 [5–9], P < 0.001). The clinical improvement rate (275/360 [76.39%]) in the HSBD group within 7 days was significantly higher than that (203/368 [55.16%]) in the control group (P < 0.001). The improvement of symptom scores in the HSBD group was higher than that in the control group (2 [1–4] vs. 1 [1–2], P < 0.001). No severe adverse events occurred. Conclusions: Our study suggested that HSBD effectively increased the negative conversion rate of SARS-CoV-2 and shortened the negative conversion time and hospitalized days in mild COVID-19 patients. Clinical trial registration: The trial was registered at Chinese Clinical Trial Registry, ChiCTR2200058668. |
| format | Article |
| id | doaj-art-91e8be761c3b4a7e9755273dcae43fb0 |
| institution | DOAJ |
| issn | 2213-4220 |
| language | English |
| publishDate | 2023-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Integrative Medicine Research |
| spelling | doaj-art-91e8be761c3b4a7e9755273dcae43fb02025-08-20T03:19:52ZengElsevierIntegrative Medicine Research2213-42202023-06-0112210095010.1016/j.imr.2023.100950Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trialBowu Chen0Yan Xue1Hua Jing2Xiaodong Wang3Peimin Zhu4Weiwei Hao5Man Li6Yueqiu Gao7Department of Hepatology, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaLaboratory of Cellular Immunity, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaNaval Medical Center, Shanghai, ChinaNursing Department, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Gastroenterology, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Gastroenterology, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaLaboratory of Cellular Immunity, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China; Corresponding authors.Department of Hepatology, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China; Laboratory of Cellular Immunity, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China; Institute of Infectious Diseases of Integrated Traditional Chinese and Western Medicine, Shanghai, China; Corresponding authors.Background: The effectiveness and safety of herbal medicine Huashibaidu granule (HSBD) in treating mild Coronavirus Disease 2019 (COVID-19) patients infected with SARS-CoV-2 remain to be identified. We aimed to evaluate the effectiveness of HSBD in mild COVID-19 patients. Methods: A prospective, non-randomized, controlled study in mild COVID-19 patients was conducted in Shanghai, China, from April 8 to May 6, 2022. Finally, 360 mild COVID-19 patients received HSBD (orally 20 g twice daily for 7 days), and 368 patients received herbal medicine placebo (orally 20 g twice daily for 7 days). The primary endpoints were the negative conversion rate of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the negative conversion time. Secondary endpoints included the hospitalized days and the improvement in the clinical condition. Results: The negative conversion rate of SARS-CoV-2 at 7 days posttreatment in the HSBD group was higher than that in the control group (95.28% vs. 82.61%, P < 0.001). The median negative conversion time in the HSBD group was markedly decreased by 2 days compared with the control group (3 [3–6] vs. 5 [4–7], P < 0.001). In addition, the median hospitalized day was shortened in the HSBD group by 1 day compared with the control group (6 [4–7] vs. 7 [5–9], P < 0.001). The clinical improvement rate (275/360 [76.39%]) in the HSBD group within 7 days was significantly higher than that (203/368 [55.16%]) in the control group (P < 0.001). The improvement of symptom scores in the HSBD group was higher than that in the control group (2 [1–4] vs. 1 [1–2], P < 0.001). No severe adverse events occurred. Conclusions: Our study suggested that HSBD effectively increased the negative conversion rate of SARS-CoV-2 and shortened the negative conversion time and hospitalized days in mild COVID-19 patients. Clinical trial registration: The trial was registered at Chinese Clinical Trial Registry, ChiCTR2200058668.http://www.sciencedirect.com/science/article/pii/S221342202300029XCOVID-19Traditional Chinese MedicineHuashibaidu granules |
| spellingShingle | Bowu Chen Yan Xue Hua Jing Xiaodong Wang Peimin Zhu Weiwei Hao Man Li Yueqiu Gao Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial Integrative Medicine Research COVID-19 Traditional Chinese Medicine Huashibaidu granules |
| title | Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial |
| title_full | Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial |
| title_fullStr | Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial |
| title_full_unstemmed | Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial |
| title_short | Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial |
| title_sort | effectiveness of chinese medicine formula huashibaidu granule on mild covid 19 patients a prospective non randomized controlled trial |
| topic | COVID-19 Traditional Chinese Medicine Huashibaidu granules |
| url | http://www.sciencedirect.com/science/article/pii/S221342202300029X |
| work_keys_str_mv | AT bowuchen effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT yanxue effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT huajing effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT xiaodongwang effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT peiminzhu effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT weiweihao effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT manli effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT yueqiugao effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial |